Literature DB >> 16421594

Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.

K Hiraoka1, M Miyamoto, Y Cho, M Suzuoki, T Oshikiri, Y Nakakubo, T Itoh, T Ohbuchi, S Kondo, H Katoh.   

Abstract

The purpose of this study was to clarify the relationship between the number of tumour-infiltrating T lymphocytes and the clinicopathological features and clinical outcome in patients with non-small-cell lung cancer (NSCLC). Tissue specimens from 109 patients who underwent surgical resection for NSCLC were immunohistochemically analysed for CD4 and CD8 expression. Patients were classified into two groups according to whether their tumours exhibited a 'high' or 'low' level of CD8(+) or CD4(+) lymphocyte infiltration. Although the level of infiltration by CD8(+) T cells alone had no prognostic significance, the survival rate for patients with both 'high' CD8(+) and 'high' CD4(+) T-cell infiltration was significantly higher than that for the other groups (log-rank test, P=0.006). Multivariate analysis indicated that concomitant high CD8(+) and high CD4(+) T-cell infiltration was an independent favourable prognostic factor (P=0.0092). In conclusion, the presence of high levels of both CD8(+) T cells and CD4(+) T cells is a significant indicator of a better prognosis for patients with NSCLC, and cooperation between these cell populations may allow a significantly more potent antitumour response than either population alone.

Entities:  

Mesh:

Year:  2006        PMID: 16421594      PMCID: PMC2361103          DOI: 10.1038/sj.bjc.6602934

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


Lung cancer is one of the most common malignancies in the world, and despite remarkable advances in diagnosis and treatment for the disease, the prognosis in most cases remains poor. Non-small-cell lung cancer (NSCLC) represents about 75–80% of all lung cancers, and its overall 5-year survival rate is less than 12–15% (Ihde, 1992; Non-small Cell Lung Cancer Collaborative Group, 1995; Jemal ). These facts make clear the need for new parameters that will allow better prognostic evaluation for this malignancy and more reliable identification of patients likely to benefit from adjuvant therapy. In a variety of human solid cancers, tumour-infiltrating T lymphocytes (TILs) are considered to play important roles in anticancer immunomechanisms of the tumour-bearing host. Among TILs, most CD8+ T cells are cytotoxic T lymphocytes that recognise particular tumour-associated antigens presented on MHC class I molecules at the cancer cell surface and possess the ability to destroy cancer cells directly. The favourable prognostic significance of the presence of tumour-infiltrating CD8+ T cells was previously reported in a variety of cancers, including colorectal cancer, oesophageal cancer, pancreatic cancer, bile duct cancer and gallbladder cancer (Naito ; Nakano ; Schumacher ; Cho ; Nakakubo ; Oshikiri ; Fukunaga ). In NSCLC, however, the relationship between patient prognosis and the presence of TILs is still obscure. The infiltration of natural killer cells or macrophages into tumours was previously found to indicate a favourable prognosis (Takeo ; Takanami ), whereas the presence of tumour-infiltrating CD8+ T cells was not found to be a predictor of patient survival (Mori ; Wakabayashi ). CD4+ T cells play a central role in orchestrating the immune response to cancer. Essentially, CD4+ T cells recognise peptides presented on MHC class II molecules expressed primarily on antigen-presenting cells. Although most tumour cells do not express MHC class II molecules, CD4+ T cells can effect an antitumour response in the absence of CD8+ T cells by secreting cytokines, such as interferon-γ (Mumberg ; Qin and Blankenstein, 2000), or by activation and recruitment of effector cells such as macrophages and eosinophils (Greenberg, 1991; Hung ). However, the main role of CD4+ T cells in the immune response to cancer is to prime CD8+ cells and maintain their proliferation. The purpose of the present study was to evaluate the infiltration of CD4+ and CD8+ T cells by immunohistochemistry in order to clarify the individual or synergistic role of TILs in NSCLC.

MATERIALS AND METHODS

Patients and tissue specimens

Tissue specimens from 109 patients who underwent surgical resection for NSCLC between 1994 and 1996 in the Department of Thoracic Surgery at Minami-Ichijo Hospital were studied. These cases were histopathologically composed of 58 cases of adenocarcinoma, 40 of squamous cell carcinoma, seven of large cell carcinoma, three of adeno-squamous cell carcinoma and one of carcinosarcoma. Surgical resection was not performed in patients presenting with distant site metastases. None of these patients received either preoperative radiation or chemotherapy. Our series included 71 men and 38 women with a mean age of 63 years (range 39–80). Follow-up data for each of these patients was collected for at least 5 years, and 52 patients (48%) died during the follow-up period. All specimens were fixed in 10% formalin and embedded in paraffin wax. Unstained 4-μm sections were then cut from paraffin blocks for immunohistochemical analysis. Histological classification of tumours was based on the World Health Organization criteria. All tumours were staged according to the pTNM pathological classification of the UICC (International Union Against Cancer) (Sobin and Wittekind, 1997).

Immunohistochemical examination

For immunohistochemical analysis, formalin-fixed and paraffin-embedded sections were deparaffinised in xylene and rehydrated through a graded series from ethanol to water. Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide for 10 min. After washing in phosphate-buffered saline (PBS, pH 7.4) twice, the sections were incubated with 10% normal goat serum for 5 min and then incubated overnight at 4°C with the primary antibodies at the following dilutions: anti-CD8 mouse monoclonal antibody (C8/144B; DAKO, Glostrup, Denmark) 1 : 50, anti-CD4 mouse monoclonal antibody (1F6; Novocastra, Newcastle, UK) 1 : 50. For negative controls, we used 10% normal mouse serum in place of primary antibody. After three additional washes, a biotinylated goat anti-mouse antibody (Histofine SAB-PO kit; Nichirei Co., Tokyo, Japan) was applied at room temperature for 30 min. After the sections were washed in PBS three times, freshly prepared 3,3′-diaminobenzidine tetrahydrochloride (Histofine Simple stain DAB Solution; Nichirei Corporation, Tokyo, Japan) was used to visualise antibody binding and the sections were washed in distilled water. Sections were counterstained with haematoxylin and mounted in Permount.

Evaluation and classification of CD8+ and CD4+ T cells

Tumour-infiltrating CD8+ T cells were classified into two groups by their location: CD8+ T cells within cancer stroma adjacent to cancer cell nests, or CD8+ T cells within the cancer cell nests themselves. For each group, we counted the number of CD8+ T cells with a magnification of × 200 (Olympus Optical Co., Ltd, Tokyo, Japan). The number of CD4+ T cells in cancer stroma were also counted and classified in the same way. Five areas containing the highest abundance of TILs were evaluated in each case. All counting was performed independently by three investigators of this study without knowledge of the patients' background or outcome, and immunoreactivity in each section was represented by the median scores.

Statistical analysis

Correlations between the numbers of both CD8+ T cells and CD4+ T cells with the patients' clinicopathological variables were analysed by the χ2 test or Fisher's exact probability test. Correlation coefficient was described as r, and r>0.7 was defined as a strong correlation. Univariate analysis of the survival data was performed using survival curves that applied the Kaplan–Meier method with log-rank analysis. The influence of variables on survival was assessed using Cox multivariate regression analysis. The risk ratio and its 95% confidence interval were recorded for each marker. Probability values of less than 0.05 were considered statistically significant in all analyses. All statistical analysis was performed using StatView version 5.0 (SAS Institute Inc., Cary, NC, USA).

RESULTS

Immunohistochemistry and classification

Tumour-infiltrating T lymphocytes were predominantly observed within the cancer stroma by immunohistochemical staining for CD8 and CD4 (Figure 1). The number of infiltrating CD8+ or CD4+ T cells in cancer stroma was overwhelmingly higher than that within cancer nests.
Figure 1

Representative immunohistochemical staining of NSCLC tumour sections. (A) Adenocarcinoma (anti-CD8 antibody; original magnification, × 200). (B) Adenocarcinoma (anti-CD4 antibody, × 200). (C) Squamous cell carcinoma (anti-CD8 antibody, × 200). (D) Squamous cell carcinoma (anti-CD8 antibody, × 400). Arrows indicate CD8-positive stained lymphocytes.

Among 109 NSCLC specimens, the mean number of infiltrating CD8+ T cells in cancer stroma was 152±107 (median 148, range 6–566), that of CD8+ T cells within cancer nests was 14±25 (median 2, range 0–121) and that of CD4+ T cells in cancer stroma was 169±152 (median 134, range 0–626). The number of CD8+ T cells in the stroma and CD8+ T cells within cancer nests of individual cases are shown in Figure 2. There was no significant correlation (r=0.381; P<0.0001) between the number of CD8+ T cells in the stroma and the number of CD8+ T cells within cancer cell nests. We utilised the mean number of infiltrating cells as a cutoff point to divide all tumours into groups as having either ‘high’ or ‘low’ infiltration by CD8+ and CD4+ cells in stromal and in nest tissue. Fifty-three cases were classified as having ‘high’ (>151) levels of CD8+ T-cell infiltration in stromal tissue and the remainder as having ‘low’ (0–151) infiltration. Thirty-one cases were classified as having ‘high’ (>14) CD8+ T-cell infiltration within cancer nests and the remainder as having ‘low’ (0–14) infiltration. Forty-four cases were classified as having ‘high’ (>168) CD4+ T-cell infiltration within stroma and the remainder as having ‘low’ (0–168) infiltration.
Figure 2

The correlation between the number of CD8+ T cells in cancer stroma and within cancer cell nests in patients with NSCLC.

Relationships between CD8+ TILs and clinicopathological variables

The relationships between the levels of infiltration by CD8+ T cells in tumour stroma or nests and various clinicopathological features are summarised in Table 1. Significant correlations with the number of CD8+ T cells in cancer stroma were noted for lymph node metastasis and pTNM stage (P=0.019 and 0.033, respectively). However, no significant correlations were found between the number of CD8+ T cells in cancer stroma and age, gender, pT classification, histopathological grading and histological type. On the other hand, the number of CD8+ T cells within cancer cell nests was significantly correlated with gender (P=0.003), histopathological grading (P=0.047) and histological type (P<0.0001). We also found that poorly differentiated tumours or squamous cell carcinomas showed significantly higher numbers of CD8+ T-cell infiltration within cancer nests than did well-differentiated tumours or tumours of other histological types. There was a strong correlation between gender (males) and histological type (squamous cell carcinoma) in the patient cohort of this study (P<0.0001). No significant correlations were found between the level of CD4+ T-cell infiltration in cancer stroma and any of the examined clinicopathological variables (data not shown).
Table 1

Relationship between CD8+ T-cell infiltration and clinicopathological features in NSCLC

  CD8+ T cells in cancer stroma
CD8+ T cells within cancer nests
Variables Low (n=56) High (n=53) P-valuea Low (n=78) High (n=31) P-valuea
Age (years)
 <6431230.14141130.317
 ⩾642530 3718 
 
Gender
 Male36350.84844270.003
 Female2018 344 
 
pT classification
 pT127200.27037100.149
 pT2–42933 4121 
 
Lymph node metastasis
 Negative34430.01956210.675
 Positive2210 2210 
 
pTNM stage
 I29380.03351160.183
 II–III2715 2715 
 
Tumour grade
 Poor490.113670.047
 Other5244 7224 
 
Histological type
 Squamous cell carcinoma21190.8581921<0.0001
 Other3534 5911 

P-value was calculated by χ2 test or Fisher's exact test.

NSCLC=non-small-cell lung cancer.

Kaplan–Meier survival analysis

Kaplan–Meier analysis revealed that the level of CD8+ T cells within cancer nests or in cancer stroma or CD4+ T cells in cancer stroma independently had no significant relationship to the survival of the patients. Survival curves constructed using the Kaplan–Meier method are shown in Figure 3. Among the 109 patients of our study, no significant difference in survival was observed between those with ‘high’ or ‘low’ levels of CD8+ T cells in cancer stroma (Figure 3A). Similarly, the level of stromal infiltration by CD4+ T cells demonstrated no prognostic significance (Figure 3B). To evaluate the possibility that a high level of both CD8+ and CD4+ T-cell infiltration in cancer stroma might correlate with favourable patient prognosis, the patients were classified into four groups: high-CD8+/high-CD4+ T cells (n=26), high-CD8+/low-CD4+ (n=27), low-CD8+/high-CD4+ (n=18) and low-CD8+/low-CD4+ T cells (n=38). The group that exhibited both highCD8+ and high CD4+ T-cell infiltration in cancer stroma demonstrated significantly higher survival rates than the rest of the patients (log-rank test, P=0.006; Figure 3C).
Figure 3

Kaplan–Meier analysis of overall survival according to (A) the level of infiltration by CD8+ T cells in cancer stroma, (B) the level of infiltration by CD4+ T cells in cancer stroma and (C) the simultaneous presence of high levels of infiltrating CD8+ T cells and CD4+ T cells in cancer stroma in patients with NSCLC. For details about the method of classification, see Materials and Methods. aHigh-CD8+/high-CD4+ group (n=26) vs others (n=83).

Multivariate analysis of CD8+/CD4+ T cells and clinicopathological variables

Multivariate analysis of the patients as grouped in the same way was performed with other clinicopathological predictors for survival time using the Cox regression model (Table 2). The results indicated that high-CD8+/high-CD4+ T cells infiltration in cancer stroma was an independent favourable prognostic factor (risk ratio, 3.221; P=0.0092). Positive lymph node metastasis and pT classification (pT2–4) also had independent unfavourable prognostic values, with a risk ratio of 2.410 (P=0.0036) and 4.502 (P<0.0001), respectively. Although histological type had prognostic significance by univariate analysis, no significance was observed by multivariate analysis.
Table 2

Univariate and multivariate analyses of T-cell infiltration status and clinicopathological features in 109 patients with NSCLC

  Kaplan–Meier (log rank) Multivariate analysis
Variables P-value Hazard ratio (95% CI) P-value
pT classification (2–4 vs 1)<0.00014.502 (2.17–9.34)<0.0001
Lymph node metastasis (positive vs negative)<0.00012.410 (1.33–4.35)0.0036
Histological type (sqamous vs other)0.00011.726 (0.95–3.13)0.729
CD8+/CD4+ T-cell infiltration (other vs high/high)0.0063.221 (1.34–7.77)0.0092

NSCLC=non-small-cell lung cancer; CI=confidence interval.

DISCUSSION

In the immune response to cancer cells, tumour-infiltrating CD8+ T cells play an essential role, recognising tumour-associated antigens presented on MHC class I molecules expressed on the cancer cell surface and directly lysing cancer cells expressing the same antigens. In previous immunohistochemical studies in a variety of cancers, larger numbers of tumour-infiltrating CD8+ T cells usually signified a stronger immune reaction against the cancer and indicated a better prognosis. In colorectal carcinomas, the presence of large numbers of CD8+ T cells within cancer cell nests was a favourable independent prognostic factor (Naito ), and a similar result was observed in oesophageal carcinoma (Schumacher ). Furthermore, we previously demonstrated the prognostic significance of infiltrating CD8+ T cells in pancreatic cancer, gallbladder cancer, bile duct cancer and oesophageal squamous cell carcinoma (Cho ; Nakakubo ; Oshikiri ; Fukunaga ). However, in NSCLC, the role of TILs for the survival of patients is still controversial. Consistent with the previous results (Mori ; Wakabayashi ), the present study demonstrated that neither CD8+ T cells within cancer cell nests nor those in cancer stroma had a significant impact on patient survival. The reasons for this discrepancy were difficult to explain, because the antitumour effect of CD8+ T cells may be circumvented by various mechanisms in the tumour cells. Tumour cells may obtain the ability to evade immune surveillance by several strategies, including a lack of adequate T-cell costimulation (Melero ; Thomas ), downregulation of cell-surface MHC class I expression (Goodenow ; Restifo ; Imboden ), dysfunction of Fas (CD95/APO1)-mediated apoptosis (Hahne ; Strand ) and secretion of immunosuppressive factors, such as transforming growth factor-β (Inge ) or interleukin-10 (Fiorentino , 1991b). Thus, the efficiency of the immune reaction against cancers can be evaded by a variety of mechanisms used by tumour cells, and these can vary, depending on the individual cancer. It will be worthwhile to investigate the effect of such immuno-evasive factors on the ability of CD8+ T cells to mount an effective response against tumour cells in NSCLC. Despite the fact that we observed no prognostic significance of high CD4+ T-cell infiltration alone, we found a synergistic effect of simultaneous high CD4+ T-cell and CD8+ T-cell infiltration in cancer stroma as a favourable prognostic factor in NSCLC. In the presence of a relatively high level of CD4+ T-cell infiltration, patients with a sufficient number of tumour-infiltrating CD8+ T cells demonstrated a significantly better prognosis. We have previously demonstrated a similar synergistic effect between tumour-infiltrating CD8+ T cells and CD4+ T cells in oesophageal squamous cell carcinoma and pancreatic adenocarcinoma (Cho ; Fukunaga ). The present study is the first report demonstrating such an effect directly observed in resected human specimens. This result suggests that cooperation between infiltrating CD4+ T cells and CD8+ T cells in tumours might be important in the suppression of the progression of NSCLC. Previous studies have demonstrated that activation of CD4+ T cells is required for immunisation of CD8+ T cells against cancer. For activation and maintenance of tumour-infiltrating CD8+ T cells, CD4+ T cells play an important role by secreting cytokines such as interleukin-2, which is required for CD8+ T-cell growth and proliferation (Rosenberg , 1998; Yoshino ; Cheng ; Wang and Rosenberg, 1999; Rosenberg, 2001; Wang, 2001; Zeng, 2001). Reduction of CD4+ T lymphocytes by administration of anti-CD4 antibody allowed human lung cancer xenografts to form orthotopically in immuno-competent mice (Hunt ). As CD4+ T cells are necessary for the full antitumour activity of CD8+ T cells, this may explain why a high level of CD8+ T-cell infiltration alone in this study did not correlate with a more favourable prognosis. In the present study, we demonstrated that the level of CD8+ T-cell infiltration in cancer stroma correlated with pTNM staging and the presence of lymph node metastasis. Although multivariate analysis demonstrated that the presence of lymph node metastasis was a significant independent unfavourable prognostic factor, this result suggests that tumour-infiltrating CD8+ T cells may not only locally but also systemically suppress metastasis in lymph tracts. Moreover, we found that the level of CD8+ T-cell infiltration within cancer cell nests had significant correlations with tumour dedifferentiation and histological subtype in NSCLC, consistent with previous reports (Mori ; Wakabayashi ). One possible reason for these results is a difference in immunogenicity of each subtype of cancer. In NSCLC, poorly differentiated cancers or squamous cell carcinomas may express larger amounts of tumour-associated antigens than other types of cancers, and hence, the number of CD8+ T cells within cancer cell nests might reflect only the peculiarities of the cancer cells in small locoregional areas. As the average number of CD8+ T cells within cancer cell nests was over 10-fold lower than that in cancer stroma in the present data, CD8+ T cells within cancer cell nests might not have a significant influence on the immune response against cancer due to the low level of antitumour immunity. In conclusion, we found that infiltrating CD8+ T cells and CD4+ T cells in NSCLC may cooperate to suppress cancer progression and their presence together appears to be an independent favourable prognostic factor in this disease. The presence of both infiltrating CD8+ T cells and CD4+ T cells in resected specimens may be a useful index for adjuvant therapies for patients with poor prognosis.
  37 in total

1.  Orthotopic human lung carcinoma xenografts in BALB/c mice immunosuppressed with anti-CD4 monoclonal antibodies and chronic alcohol consumption.

Authors:  J D Hunt; E G Robert; A W Zieske; A P Bautista; M Bukara; D Lei; J E Shellito; S Nelson; J K Kolls; N Skrepnik
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

2.  The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.

Authors:  M Imboden; K R Murphy; A L Rakhmilevich; Z C Neal; R Xiang; R A Reisfeld; S D Gillies; P M Sondel
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

3.  Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma.

Authors:  G R Thomas; Z Chen; M N Oechsli; F J Hendler; C Van Waes
Journal:  Int J Cancer       Date:  1999-07-30       Impact factor: 7.396

4.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors:  Z Qin; T Blankenstein
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

5.  CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

Authors:  D Mumberg; P A Monach; S Wanderling; M Philip; A Y Toledano; R D Schreiber; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

6.  The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma.

Authors:  I Takanami; K Takeuchi; M Giga
Journal:  J Thorac Cardiovasc Surg       Date:  2001-06       Impact factor: 5.209

7.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

8.  Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.

Authors:  T H Inge; S K Hoover; B M Susskind; S K Barrett; H D Bear
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

9.  CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma.

Authors:  Akira Fukunaga; Masaki Miyamoto; Yasushi Cho; Soichi Murakami; You Kawarada; Taro Oshikiri; Kentaro Kato; Takanori Kurokawa; Masato Suzuoki; Yoshihiro Nakakubo; Kei Hiraoka; Tomoo Itoh; Toshiaki Morikawa; Shunichi Okushiba; Satoshi Kondo; Hiroyuki Katoh
Journal:  Pancreas       Date:  2004-01       Impact factor: 3.327

10.  Role of tumor-associated macrophages in lung cancer.

Authors:  S Takeo; K Yasumoto; A Nagashima; H Nakahashi; K Sugimachi; K Nomoto
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

View more
  171 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer.

Authors:  Asa Andersson; Minu K Srivastava; Marni Harris-White; Min Huang; Li Zhu; David Elashoff; Robert M Strieter; Steven M Dubinett; Sherven Sharma
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 3.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

Review 4.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

5.  Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma.

Authors:  Erin Schenk; Jennifer Boland; Aaron Mansfield; Marie Christine Aubry; Allan Dietz
Journal:  Med Oncol       Date:  2017-07-15       Impact factor: 3.064

Review 6.  Primary immune surveillance: some like it hot.

Authors:  Joseph J Skitzki; Qing Chen; W C Wang; Sharon S Evans
Journal:  J Mol Med (Berl)       Date:  2007-08-18       Impact factor: 4.599

7.  Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.

Authors:  Elly Marcq; Vasiliki Siozopoulou; Jorrit De Waele; Jonas van Audenaerde; Karen Zwaenepoel; Eva Santermans; Niel Hens; Patrick Pauwels; Jan P van Meerbeeck; Evelien L J Smits
Journal:  Oncoimmunology       Date:  2016-11-28       Impact factor: 8.110

Review 8.  Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

Authors:  Julie R Brahmer; Drew M Pardoll
Journal:  Cancer Immunol Res       Date:  2013-07-22       Impact factor: 11.151

Review 9.  Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.

Authors:  Kazuhiko Shien; Vassiliki A Papadimitrakopoulou; Ignacio I Wistuba
Journal:  Lung Cancer       Date:  2016-06-21       Impact factor: 5.705

10.  Lymphopenia and its association with survival in patients with locally advanced cervical cancer.

Authors:  Emily S Wu; Titilope Oduyebo; Lauren P Cobb; Diana Cholakian; Xiangrong Kong; Amanda N Fader; Kimberly L Levinson; Edward J Tanner; Rebecca L Stone; Anna Piotrowski; Stuart Grossman; Kara Long Roche
Journal:  Gynecol Oncol       Date:  2015-11-11       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.